Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTR1E | P28566 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900070 | 0.97 | AKR1C1 (0.59) | NPSR1AKR1C1MAPTHTR1ES1PR3 | |
| SCHEMBL1769201 | 0.93 | NPSR1 (0.50) | NPSR1AKR1C1MAPTHTR1ES1PR3 | |
| SCHEMBL3904809 | 0.85 | L3MBTL1 (0.64) | NPSR1AKR1C1MAPTHTR1ES1PR3 | |
| SCHEMBL17109512 | 0.85 | NPSR1 (0.53) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL5369238 | 0.85 | NPSR1 (0.53) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL2815457 | 0.81 | NPSR1 (0.57) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL5372386 | 0.81 | NPSR1 (0.57) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL6676255 | 0.81 | AKR1C1 (0.53) | NPSR1AKR1C1MAPTMEN1KMT2A | |
| SCHEMBL3227451 | 0.81 | MEN1 (0.58) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL3909752 | 0.81 | ALDH1A1 (0.55) | NPSR1MAPTHTR1ES1PR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1161962-A | Sulphonic-acid-amide derivative | KONO PHARMACEUTICAL IND K K (JP) | 1997-10-15 | — | — | CN | claimed |
| EP-3661909-B1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3694502-B1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11319283-B2 | Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11208407-B2 | Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200277252-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3694502-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200216443-A1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3661909-A1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019074747-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
| EP-1276748-B1 | 13-SUBSTITUTED MILBEMYCIN DERIVATIVES, THEIR PREPARATION AND THEIR USE AGAINST INSECTS AND OTHER PESTS | SANKYO LIFETECH COMPANY LTD (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-6653342-B2 | Acaricidal, insecticidal and anthelmintic activity on plants and animals; such as 13-(1-(4-aminophenyl)cyclopentane-carbonyloxy)-5-hydroxymilbemycin A4 | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030139601-A1 | 13-substituted milbemycin derivatives, their preparation and their use against insects and other pests | SANKYO COMPANY, LIMITED (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1276748-A1 | 13-SUBSTITUTED MILBEMYCIN DERIVATIVES, THEIR PREPARATION AND THEIR USE AGAINST INSECTS AND OTHER PESTS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001083500-A1 | 13-SUBSTITUTED MILBEMYCIN DERIVATIVES, THEIR PREPARATION AND THEIR USE AGAINST INSECTS AND OTHER PESTS | SANKYO COMPANY, LIMITED (JP) | 2001-11-08 | — | — | WO | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
| CN-1161962-A | Sulphonic-acid-amide derivative | KONO PHARMACEUTICAL IND K K (JP) | 1997-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216443-A1 | NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | NPSR1 1224/4885AKR1C1 1194/4885MAPT 1295/4885 |
| US-11319283-B2 | Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, KYNU | NPSR1 1280/4885AKR1C1 1340/4885MAPT 1235/4885 |
| US-20030139601-A1 | 13-substituted milbemycin derivatives, their preparation and their use against insects and other pests | MRM1, CYCS, RPS27 | NPSR1 3879/4885AKR1C1 1193/4885MAPT 4683/4885 |
| US-20200277252-A1 | NOVEL SUBSTITUTED CYCLOBUTYLBENZENE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | NPSR1 1282/4885AKR1C1 1122/4885MAPT 1513/4885 |
| US-11208407-B2 | Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | NPSR1 1126/4885AKR1C1 1358/4885MAPT 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.